Patient-derived xenograft (PDX) models in basic and translational breast cancer research.

2.50
Hdl Handle:
http://hdl.handle.net/10541/620142
Title:
Patient-derived xenograft (PDX) models in basic and translational breast cancer research.
Authors:
Dobrolecki, L; Airhart, S; Alferez, Denis G; Aparicio, S; Behbod, F; Bentires-Alj, M; Brisken, C; Bult, C; Cai, S; Clarke, R; Dowst, H; Ellis, M; Gonzalez-Suarez, E; Iggo, R; Kabos, P; Li, S; Lindeman, G; Marangoni, E; McCoy, A; Meric-Bernstam, F; Piwnica-Worms, H; Poupon, M; Reis-Filho, J; Sartorius, C; Scabia, V; Sflomos, G; Tu, Y; Vaillant, F; Visvader, J; Welm, A; Wicha, M; Lewis, M
Abstract:
Patient-derived xenograft (PDX) models of a growing spectrum of cancers are rapidly supplanting long-established traditional cell lines as preferred models for conducting basic and translational preclinical research. In breast cancer, to complement the now curated collection of approximately 45 long-established human breast cancer cell lines, a newly formed consortium of academic laboratories, currently from Europe, Australia, and North America, herein summarizes data on over 500 stably transplantable PDX models representing all three clinical subtypes of breast cancer (ER+, HER2+, and "Triple-negative" (TNBC)). Many of these models are well-characterized with respect to genomic, transcriptomic, and proteomic features, metastatic behavior, and treatment response to a variety of standard-of-care and experimental therapeutics. These stably transplantable PDX lines are generally available for dissemination to laboratories conducting translational research, and contact information for each collection is provided. This review summarizes current experiences related to PDX generation across participating groups, efforts to develop data standards for annotation and dissemination of patient clinical information that does not compromise patient privacy, efforts to develop complementary data standards for annotation of PDX characteristics and biology, and progress toward "credentialing" of PDX models as surrogates to represent individual patients for use in preclinical and co-clinical translational research. In addition, this review highlights important unresolved questions, as well as current limitations, that have hampered more efficient generation of PDX lines and more rapid adoption of PDX use in translational breast cancer research.
Affiliation:
The Lester and Sue Smith Breast Center, Departments of Molecular and Cellular Biology and Radiology, Baylor College of Medicine, Houston, TX, 77030
Citation:
Patient-derived xenograft (PDX) models in basic and translational breast cancer research. 2016, 35 (4):547-573 Cancer Metastasis Rev
Journal:
Cancer Metastasis Reviews
Issue Date:
Dec-2016
URI:
http://hdl.handle.net/10541/620142
DOI:
10.1007/s10555-016-9653-x
PubMed ID:
28025748
Additional Links:
http://link.springer.com/article/10.1007%2Fs10555-016-9653-x
Type:
Article
Language:
en
ISSN:
1573-7233
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorDobrolecki, Len
dc.contributor.authorAirhart, Sen
dc.contributor.authorAlferez, Denis Gen
dc.contributor.authorAparicio, Sen
dc.contributor.authorBehbod, Fen
dc.contributor.authorBentires-Alj, Men
dc.contributor.authorBrisken, Cen
dc.contributor.authorBult, Cen
dc.contributor.authorCai, Sen
dc.contributor.authorClarke, Ren
dc.contributor.authorDowst, Hen
dc.contributor.authorEllis, Men
dc.contributor.authorGonzalez-Suarez, Een
dc.contributor.authorIggo, Ren
dc.contributor.authorKabos, Pen
dc.contributor.authorLi, Sen
dc.contributor.authorLindeman, Gen
dc.contributor.authorMarangoni, Een
dc.contributor.authorMcCoy, Aen
dc.contributor.authorMeric-Bernstam, Fen
dc.contributor.authorPiwnica-Worms, Hen
dc.contributor.authorPoupon, Men
dc.contributor.authorReis-Filho, Jen
dc.contributor.authorSartorius, Cen
dc.contributor.authorScabia, Ven
dc.contributor.authorSflomos, Gen
dc.contributor.authorTu, Yen
dc.contributor.authorVaillant, Fen
dc.contributor.authorVisvader, Jen
dc.contributor.authorWelm, Aen
dc.contributor.authorWicha, Men
dc.contributor.authorLewis, Men
dc.date.accessioned2017-02-07T09:55:47Z-
dc.date.available2017-02-07T09:55:47Z-
dc.date.issued2016-12-
dc.identifier.citationPatient-derived xenograft (PDX) models in basic and translational breast cancer research. 2016, 35 (4):547-573 Cancer Metastasis Reven
dc.identifier.issn1573-7233-
dc.identifier.pmid28025748-
dc.identifier.doi10.1007/s10555-016-9653-x-
dc.identifier.urihttp://hdl.handle.net/10541/620142-
dc.description.abstractPatient-derived xenograft (PDX) models of a growing spectrum of cancers are rapidly supplanting long-established traditional cell lines as preferred models for conducting basic and translational preclinical research. In breast cancer, to complement the now curated collection of approximately 45 long-established human breast cancer cell lines, a newly formed consortium of academic laboratories, currently from Europe, Australia, and North America, herein summarizes data on over 500 stably transplantable PDX models representing all three clinical subtypes of breast cancer (ER+, HER2+, and "Triple-negative" (TNBC)). Many of these models are well-characterized with respect to genomic, transcriptomic, and proteomic features, metastatic behavior, and treatment response to a variety of standard-of-care and experimental therapeutics. These stably transplantable PDX lines are generally available for dissemination to laboratories conducting translational research, and contact information for each collection is provided. This review summarizes current experiences related to PDX generation across participating groups, efforts to develop data standards for annotation and dissemination of patient clinical information that does not compromise patient privacy, efforts to develop complementary data standards for annotation of PDX characteristics and biology, and progress toward "credentialing" of PDX models as surrogates to represent individual patients for use in preclinical and co-clinical translational research. In addition, this review highlights important unresolved questions, as well as current limitations, that have hampered more efficient generation of PDX lines and more rapid adoption of PDX use in translational breast cancer research.en
dc.language.isoenen
dc.relation.urlhttp://link.springer.com/article/10.1007%2Fs10555-016-9653-xen
dc.rightsArchived with thanks to Cancer metastasis reviewsen
dc.titlePatient-derived xenograft (PDX) models in basic and translational breast cancer research.en
dc.typeArticleen
dc.contributor.departmentThe Lester and Sue Smith Breast Center, Departments of Molecular and Cellular Biology and Radiology, Baylor College of Medicine, Houston, TX, 77030en
dc.identifier.journalCancer Metastasis Reviewsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.